What question did this study set out to answer?

The study aims to evaluate the effects of PCSK9 inhibition on renal lipotoxicity and its mechanism through AMPK activation in diabetic kidney disease.

March 28, 2026Open Access

WCN26-6551 PCSK9 Inhibition Attenuates Renal Lipotoxicity by Activating AMPK in Diabetic Kidney Disease

Puntos clave

The study aims to evaluate the effects of PCSK9 inhibition on renal lipotoxicity and its mechanism through AMPK activation in diabetic kidney disease.
Panel discussions were conducted to gather expert opinions.
Focus on treatment strategies for adults with chronic kidney disease (CKD) and type 2 diabetes (T2D).
Assess the role of SGLT2 inhibitors and GLP-1 receptor agonists in treatment.
Panelists recommended SGLT2 inhibitors as foundational therapy.
GLP-1 receptor agonists were endorsed for patients with obesity and metabolic risks.
Early kidney protection was emphasized as a treatment goal.

Resumen

Conclusion:Based on Round 1, panelists favored SGLT2is as a foundational therapy for adults with CKD and T2D, with GLP-1 RAs considered for obesity, metabolic risk, ASCVD, or in combination with SGLT2i for persistent kidney disease progression.These initial insights emphasize kidney protection as an early treatment goal.

Me gusta

Guardar

Ver artículo completo